KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$37.5 million.

  • Sarepta Therapeutics' Free Cash Flow rose 6524.8% to -$37.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$381.1 million, marking a year-over-year increase of 1898.39%. This contributed to the annual value of -$342.7 million for FY2024, which is 4060.93% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Free Cash Flow stood at -$37.5 million for Q3 2025, which was up 6524.8% from $229.5 million recorded in Q2 2025.
  • Sarepta Therapeutics' Free Cash Flow's 5-year high stood at $229.5 million during Q2 2025, with a 5-year trough of -$627.1 million in Q1 2025.
  • In the last 5 years, Sarepta Therapeutics' Free Cash Flow had a median value of -$106.7 million in 2022 and averaged -$115.4 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 21826.72% in 2022, then surged by 171364.5% in 2025.
  • Sarepta Therapeutics' Free Cash Flow (Quarter) stood at -$31.5 million in 2021, then crashed by 218.27% to -$100.4 million in 2022, then rose by 26.57% to -$73.7 million in 2023, then surged by 173.23% to $54.0 million in 2024, then tumbled by 169.53% to -$37.5 million in 2025.
  • Its Free Cash Flow was -$37.5 million in Q3 2025, compared to $229.5 million in Q2 2025 and -$627.1 million in Q1 2025.